Moolec Science (MLECW) Gross Margin (2023 - 2024)
Moolec Science (MLECW) posted Gross Margin of 25.52% for Q4 2024, down 2789.22% sequentially from 0.95% in Q3 2024, and down 11757.0% YoY from N/an in Q1 2024.
Moolec Science (MLECW) Gross Margin (2023 - 2024) Analysis & Trends
Moolec Science has reported Gross Margin for 2 years, with the latest figure at 25.52% in Q4 2024.
- Quarterly Gross Margin fell 11757.0% year-over-year to 25.52% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 8.16% (changed N/A YoY) and the FY2024 annual result came in at 3317.26%, down 1707943.0% from the prior year.
- Gross Margin fell to 25.52% in Q4 2024 per MLECW's latest filing, from 0.95% in the prior quarter.
- Over five years, Gross Margin peaked at 92.05% in Q4 2023 and troughed at 25.52% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -25.52% |
| Sep 30, 2024 | 0.95% |
| Jun 30, 2024 | -4.70% |
| Mar 31, 2024 | 4.35% |
| Dec 31, 2023 | 92.05% |
| Sep 30, 2023 | 12.67% |